BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 30762909)

  • 1. JAK inhibitors for alopecia areata: a systematic review and meta-analysis.
    Phan K; Sebaratnam DF
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):850-856. PubMed ID: 30762909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
    Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
    J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
    Wei D; Chen Y; Shen Y; Xie B; Song X
    Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
    Ramot Y; Zlotogorski A
    Harefuah; 2020 Jan; 159(1):38-42. PubMed ID: 31930807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus kinase inhibitors for alopecia areata.
    King BA; Craiglow BG
    J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase inhibitors for alopecia areata: A narrative review.
    Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
    Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drugs for alopecia areata: JAK inhibitors.
    Iorizzo M; Tosti A
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):77-81. PubMed ID: 29466675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus Kinase Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis.
    Liu M; Gao Y; Yuan Y; Yang K; Shen C; Wang J; Tian J
    JAMA Netw Open; 2023 Jun; 6(6):e2320351. PubMed ID: 37368402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK inhibition in the treatment of alopecia areata - a promising new dawn?
    Ismail FF; Sinclair R
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):43-51. PubMed ID: 31865802
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review.
    de Oliveira AB; Alpalhão M; Filipe P; Maia-Silva J
    Dermatol Ther; 2019 Sep; 32(5):e13053. PubMed ID: 31381252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
    Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
    J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
    Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
    JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus kinase inhibitors: An innovative treatment for alopecia areata.
    Park H; Yu DA; Kwon O
    J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of janus kinase inhibitors in the treatment of alopecia areata.
    Triyangkulsri K; Suchonwanit P
    Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of JAK inhibitors in the treatment of alopecia areata in children: a systematic review and meta-analysis.
    Chen Y; Zhu H; Shen Y; Zhu Y; Sun J; Dai Y; Song X
    J Dermatolog Treat; 2022 Dec; 33(8):3143-3149. PubMed ID: 36214579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
    Mackay-Wiggan J; Jabbari A; Nguyen N; Cerise JE; Clark C; Ulerio G; Furniss M; Vaughan R; Christiano AM; Clynes R
    JCI Insight; 2016 Sep; 1(15):e89790. PubMed ID: 27699253
    [No Abstract]   [Full Text] [Related]  

  • 18. JAK-inhibitors in dermatology: current evidence and future applications.
    Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
    J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK Inhibitors for Treatment of Alopecia Areata.
    Wang EHC; Sallee BN; Tejeda CI; Christiano AM
    J Invest Dermatol; 2018 Sep; 138(9):1911-1916. PubMed ID: 30057345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.
    Yu DA; Kim YE; Kwon O; Park H
    Indian J Dermatol Venereol Leprol; 2021; 87(5):621-627. PubMed ID: 34379968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.